As investors examine sectors and opportunities for timely investments, energy is always of interest. The S&P finished 2022 with record gains in its energy sector…
April 11, 2023
Prism MarketView Market Insights: What’s Ahead This Week
Investors are settling into a week with anticipation for the latter half as they tee up for a big macro week coupled with a kickoff…
April 03, 2023
Lipella Pharmaceuticals Reports 2022 Earnings; Completes Initial Public Offering, Achieves Key Milestones
Clinical stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO), has reported its 2022 financial results and provided a business update.
March 28, 2023
OpenLocker (OLKR) Creates “FanTech” Opportunity for Fans and Student-Athletes of FAU and UConn
All eyes of college sports fanatics were tuned into the Elite Eight round of the March Madness NCAA Men’s Basketball tournament, this weekend. Now, only…
SuperCom Ltd. (SPCB) is a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors. SuperCom presents an impressive group of experts in…
March 01, 2023
A Pivotal Year Ahead for Quoin Pharmaceuticals
Company celebrates key milestones and charts path from clinical-stage to commercial. Since commencing trading on Nasdaq in October 2021, Quoin Pharmaceuticals ( Nasdaq: QNRX )…
The skin is the body’s largest organ, a barrier protecting us from infectious agents and allergens and preventing water loss. Its healthy functioning is critical…
December 21, 2022
Bionik Eyes $4.9 Billion Global Neurorehabilitation Devices Market with New Strategic Direction
Robotics and neurological recovery solutions company Bionik Laboratories (OTCPINK: BKNL), has unveiled a new strategic approach to rehabilitating stroke survivors and others with functional and mobility…
Lexaria Bioscience (Nasdaq): LEXX is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and diabetes, two of the world’s biggest public health crises….
September 21, 2022
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields “Remarkable” Results
Lexaria Bioscience (Nasdaq: LEXX) (Nasdaq: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, DehydraTECH-CBD, offers…
Biotechnology company, Oxford BioDynamics (AIM:OBD), is poised for successful commercialization of its precision medicine tests for oncology. Any seasoned investor will tell you that investing…